Dose-modified abiraterone acetate (AA) in men with metastatic castration-resistant prostate cancer (mCRPC): The Princess Margaret Cancer Centre (PM) experience

被引：0
|
作者：
Leibowitz-Amit, Raya
Atenafu, Eshetu G.
Seah, Jo-An
Templeton, Arnoud J.
Vera-Badillo, Francisco Emilio
Solow, Henry L.
Knox, Jennifer J.
Sridhar, Srikala S.
Tannock, Ian
Joshua, Anthony Michael
机构：
[1] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
[2] Univ Toronto, Dept Med, Toronto, ON, Canada
[3] Princess Margaret Canc Ctr, Dept Biostat, Toronto, ON, Canada
[4] Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada
[5] Univ Toronto, Univ Hlth Network, Princess Margaret Canc Ctr, Dept Med, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 04期
关键词：
D O I：
10.1200/jco.2014.32.4_suppl.61
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
61
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Initial experience with abiraterone acetate in patients with castration-resistant prostate cancer
    Beardo-Villar, P.
    Ledo-Cepero, M. J.
    Gavira-Moreno, R.
    Soto-Delgado, M.
    Soto-Vittalba, J.
    Alvarez-Ossorio, J. L.
    Juarez-Soto, A.
    [J]. ACTAS UROLOGICAS ESPANOLAS, 2014, 38 (05): : 339 - 345
  • [32] Results of a phase II trial of abiraterone acetate (AA) combined with dutasteride (DUT) for men with metastatic castration resistant prostate cancer (mCRPC).
    McKay, Rana R.
    Werner, Lillian
    Zukotynski, Katherine A.
    Domachevsky, Liran
    Elfiky, Aymen
    Pomerantz, Mark M.
    Bubley, Glenn J.
    Montgomery, Robert B.
    Kantoff, Philip W.
    Taplin, Mary-Ellen
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [33] Germline variant in SLCO2B1 and response to abiraterone acetate plus prednisone (AA) in men with metastatic castration-resistant prostate cancer (mCRPC).
    Hahn, Andrew W.
    Patel, Darshan
    Gill, David Michael
    Froerer, Camryn
    Nussensveig, Roberto
    Poole, Austin
    Hale, Peter
    Farnham, James M.
    Maughan, Benjamin Louis
    Cannon-Albright, Lisa A.
    Agarwal, Neeraj
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [34] From trial to practice: The Princess Margaret Hospital (PMH) experience with docetaxel and prednisone for men with metastatic castration resistant prostate cancer (mCRPC)
    Templeton, Arnoud
    Wang, Lisa
    Vera-Badillo, Francisco
    Attalla, Mirna
    De Gouveia, Paulo
    Leibowitz-Amit, Raya
    Knox, Jennifer J.
    Moore, Malcolm J.
    Sridhar, Srikala S.
    Joshua, Anthony Michael
    Tannock, Ian
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [35] Prevalence of oligoprogressive, metastatic castration-resistant prostate cancer (mCRPC) amenable to stereotactic ablative radiotherapy (SABR) in men undergoing abiraterone acetate (AA) therapy.
    McDonald, Erica
    Cheng, Sierra
    Arciero, Vanessa S.
    Saluja, Ronak
    Zukotynski, Katherine A.
    Cheung, Patrick
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [36] Prevalence of oligoprogressive, metastatic castration-resistant prostate cancer (mCRPC) amenable to stereotactic ablative radiotherapy (SABR) in men undergoing abiraterone acetate (AA) therapy.
    McDonald, Erica
    Cheng, Sierra
    Arciero, Vanessa Sarah
    Saluja, Ronak
    Zukotynski, Katherine A.
    Cheung, Patrick
    Emmenegger, Urban
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [37] Independent assessment of TP53 and PTEN as predictors of response to enzalutamide (ENZ) or abiraterone acetate (AA) in men with metastatic castration-resistant prostate cancer (mCRPC).
    Hahn, Andrew W.
    Rathi, Nityam
    Gill, David Michael
    VanAlstine, Sidney
    Poole, Austin
    Agarwal, Neeraj
    Maughan, Benjamin Louis
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [38] Outcomes with different sequences of cabazitaxel and abiraterone acetate following dooetaxel in metastatic castration-resistant prostate cancer (mCRPC)
    Sonpavde, G.
    Bhor, M.
    Hennessy, D.
    Bhowmik, D.
    Shen, L.
    Nicacio, L.
    Rembert, D.
    Yap, M.
    Dhanda, R.
    Schnadig, I.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S698 - S698
  • [39] The economics of abiraterone acetate for castration-resistant prostate cancer
    Dellis, Athanasios
    Papatsoris, Athanasios G.
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (02) : 175 - 179
  • [40] Abiraterone experience in a patient with metastatic castration-resistant prostate cancer on hemodialysis
    Eryilmaz, Melek Karakurt
    Karaagac, Mustafa
    [J]. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (08) : 2031 - 2034
12345